Pharmaceutical Product Development Inc

Type: Company
Name: Pharmaceutical Product Development Inc
First reported Oct 28 2014 - Updated Oct 28 2014 - 1 reports

Newly-Formed DPx Holdings Buys Gallus BioPharmaceuticals CMO

DPx Holdings B.V, the result of a $2.65 billion transaction between JLL Partners and Royal DSM finalized in March , has completed the transaction to acquire Gallus BioPharmaceuticals, LLC, a leading St. Louis-based contract manufacturing company specializing ... [Published Pharmaceutical Manufacturing Magazine - Oct 28 2014]
First reported Oct 28 2014 - Updated Oct 28 2014 - 2 reports

Knight Therapeutics Inc. Continues to Execute Its Innovative Pharmaceutical Product Sourcing Strategy

MONTREAL, QUEBEC -- (Marketwired) -- 10/28/14 -- Knight Therapeutics Inc. ( TSX: GUD ) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that it has invested CAD$30 million into Teralys Capital Innovation Fund LP ("Teralys ... [Published Crawford Financial Planning - Oct 28 2014]
First reported Oct 27 2014 - Updated Oct 27 2014 - 1 reports

Hospital Asset Management Market – Pharmaceutical Products & Applications – 2017

[279 Pages Report] Hospital Asset Management Market report categorizes the global market by Applications (Wi-Fi RTLS, RFID), Products (IR, Ultrasound, Equipment & Patient Tracking, Staff Safety, Temperature & Humidity Monitoring, Drug Counterfeit) & by ... [Published ListFree.Org - Oct 27 2014]
First reported Oct 24 2014 - Updated Oct 24 2014 - 1 reports

PPD Renews Commitment to PPD Beach2Battleship Triathlon

Pharmaceutical Product Development, LLC ( PPD ) today announced it has renewed its commitment as title sponsor of the annual PPD Beach2Battleship Triathlon . PPD has supported the annual iron-distance…Click to Continue » ... [Published Fort Mills Times - Oct 24 2014]
First reported Oct 23 2014 - Updated Oct 23 2014 - 1 reports

Workshop: A Study in the Application of Vibrational Spectroscopy to Pharmaceutical Product Analysis

– 9:00 am -4:00 pmSomerset, NJBruker is pleased to present a free, two-part workshop on applying Infrared and Raman spectroscopy to the Analysis of Pharmaceutical Products. The first part, occuring in the morning will be focused on analytical applications ... [Published Pharmaceutical Manufacturing Magazine - Oct 23 2014]
First reported Oct 23 2014 - Updated Oct 23 2014 - 1 reports

ASEAN boosts cooperation on pharmaceutical industry

Representatives of the ASEAN Pharmaceutical Product Working Group (PPWG) discussed bioequivalence study reports on the bloc’s pharmaceutical products in a workshop on October 21-22.The event was jointly organised by the ASEAN Consultative Committee on ... [Published VietnamPlus - Oct 23 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 4 reports

ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles

EDISON, N.J., Oct. 16, 2014 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has entered into an agreement ... [Published Nasdaq - Oct 16 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Thousands of Illegal Pharmaceutical Products May Have Entered Asian American Community

Brian Wong (布萊恩‧黃) of Los Angeles County Department of Public Health asks Asian Americans not to buy any counterfeit drugs. Thousands of illegal pharmaceutical products -- from fake steroids to phony pain relievers to bogus miracle cures -- were confiscated ... [Published World Journal - Oct 16 2014]
First reported Oct 14 2014 - Updated Oct 15 2014 - 2 reports

SELLAS selects PPD as strategic CRO partner to advance Zolpidem and WT1 cancer vaccine

SELLAS Life Sciences Group, a Swiss-based development-stage biopharmaceutical company, has signed a definitive master service agreement with Pharmaceutical Product Development (PPD), a leading global contract research organization (CRO), to advance and ... [Published PBR - News - Oct 15 2014]
First reported Oct 06 2014 - Updated Oct 06 2014 - 1 reports

The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India

NBER Working Paper No. 20548Issued in October 2014NBER Program(s):    DEV     HC     HE     IO     PE     PRIn 2005, as the result of a World Trade Organization mandate, India began to implement product patents for pharmaceuticals that were compliant ... [Published National Bureau of Economic Research - Oct 06 2014]
First reported Oct 02 2014 - Updated Oct 02 2014 - 3 reports

Knight to invest 19.5 million euros in Forbion III

Mr. Jeffrey Kadanoff reportsKNIGHT THERAPEUTICS INC. EXPANDS ITS INNOVATIVE PHARMACEUTICAL PRODUCT SOURCING STRATEGYKnight Therapeutics Inc. has expanded its innovative pharmaceutical product sourcing strategy for the Canadian market. This strategy is ... [Published Stockwatch - Oct 02 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 2 reports

DPx Holdings B.V. Completes Acquisition of Gallus BioPharmaceuticals

) - DPx Holdings B.V., privately owned by JLL Partners and Royal DSM and the parent company of Patheon, announces that it has completed the transaction to acquire Gallus BioPharmaceuticals, LLC, a leading contract manufacturing company specializing in ... [Published Stockboard Media Inc. - Sep 30 2014]

Quotes

Sanofi Chief Executive Officer, Christopher A Viehbacher commented: "We are pleased with our performance in the third quarter. We achieved solid Business EPS growth driven by continued strong contribution from our growth platforms, allowing us to confirm 2014 outlook. Growth platforms reached over 78% of sales and grew 10%. We have recently seen a more challenging U S diabetes price environment which will impact our diabetes sales throughout 2015, while growth platforms globally are expected to continue to show solid growth. At the same time, our pipeline delivered strong results, with the release of exciting Phase III data for alirocumab and our Dengue vaccine, the entry of dupilumab in Phase III as well as the FDA approval of Cerdelga? and the licensing of Afrezza."
"Together with our team, the PlasmaTech Bio SAB will implement and provide valuable guidance as we advance our development in proprietary plasma-derived therapeutics" stated Scott Schorer
...Gene Zurlo, newly appointed Chairman of the Scientific Advisory Board, commented, "This is an exciting time for PlasmaTech Biopharmaceuticals, Inc., with its many promising commercial opportunities that the Company has in its sights. Given the recent significant increase in demand for plasma-derived therapeutics, I am excited to join a team that is focused on combining a novel high-yield plasma fractionation process with existing company expertise to drive commercialization of high-quality therapeutics. I look forward to being a part of the company's success."
...with key life science companies to help secure Canadian product rights for Knight," said Jonathan Ross Goodman, President and CEO of Knight. "We have now committed approximately $70 million of the $130 million we intend to invest into this strategy."

More Content

All (145) | News (112) | Reports (0) | Blogs (24) | Audio/Video (0) | Fact Sheets (3) | Press Releases (2)
sort by: Date | Relevance
Foreign Trade Statistics of the Philippines: Fi... [Published Philippines National Statistics Office - 6 hours ago]
Sanofi Delivers Business EPS Growth of 10.3% at... [Published Pharmacy Choice - 15 hours ago]
The Cloud Meets GMP Regulations – Part 2: SaaS ... [Published Scientific Computing - 21 hours ago]
Market Update (NYSE:LLY): Lilly to Present Reco... [Published Jutia Group - 22 hours ago]
Stock Update: Abbott Laboratories (NYSE:ABT) – ... [Published Jutia Group - Oct 29 2014]
PlasmaTech Biopharmaceuticals Appoints World Le... [Published TheStreet.com - Oct 29 2014]
PlasmaTech Biopharmaceuticals Appoints World Le... [Published Staten Island Live - Oct 29 2014]
Newly-Formed DPx Holdings Buys Gallus BioPharma... [Published Pharmaceutical Manufacturing Magazine - Oct 28 2014]
More Than 20 Patheon Scientists to Present at A... [Published 4 Traders - Oct 28 2014]
Knight Therapeutics Inc. Continues to Execute I... [Published Crawford Financial Planning - Oct 28 2014]
Knight Therapeutics Inc. Continues to Execute I... [Published Marketwire - Breaking News Releases - Oct 28 2014]
Plunkett's Biotech & Genetics Industry Trends &... [Published MarketResearch.com - Oct 28 2014]
Determination That DIAMOX (Acetazolamide) Intra... [Published Pharmacy Choice - Oct 28 2014]
Stock Update (NYSE:LLY): Lilly Responds to Deci... [Published Jutia Group - Oct 28 2014]
Hospital Asset Management Market – Pharmaceutic... [Published ListFree.Org - Oct 27 2014]
Patheon Inc. To Present Multiple Scientific Fin... [Published BioSpace - Oct 27 2014]
Graphic wins Ghana Made award [Published Graphic Ghana - Oct 27 2014]
Frytol adjudged Best Ghana Made Product of the ... [Published GhanaWeb - Oct 25 2014]
Transcept Pharmaceuticals : Reports Special Div... [Published 4 Traders - Oct 25 2014]
PPD, Inc. Renews Commitment To PPD Beach2Battle... [Published BioSpace - Oct 24 2014]
PPD Renews Commitment to PPD Beach2Battleship T... [Published Fort Mills Times - Oct 24 2014]
Healthcare Sector Comment – October 2014 [Published Clearwater Corporate Finance - Oct 24 2014]
Workshop: A Study in the Application of Vibrati... [Published Pharmaceutical Manufacturing Magazine - Oct 23 2014]
ASEAN Develops Mutual Recognition Arrangement f... [Published Pharmacy Choice - Oct 23 2014]
ASEAN boosts cooperation on pharmaceutical indu... [Published VietnamPlus - Oct 23 2014]
Stock Update (NYSE:LLY): Lilly, Zymeworks Annou... [Published Jutia Group - Oct 22 2014]
Company Update (NYSE:ABT): Abbott Reports Third... [Published Jutia Group - Oct 22 2014]
ASEAN develops mutual recognition arrangement f... [Published Jakarta Post - Oct 22 2014]
Sellas signs up PPD as a preferred partner [Published Outsourcing Pharma - Oct 21 2014]
FUJIFILM : The production of Avigan(R) Tablet 2... [Published 4 Traders - Oct 21 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Knight Therapeutics Inc. Continues to Execute I... [Published Marketwire - Breaking News Releases - Oct 28 2014]
MONTREAL, QUEBEC--(Marketwired - Oct. 28, 2014) - Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that it has invested CAD$30 million into Teralys Capital Innovation Fund LP ("Teralys ...
ContraVir Pharmaceuticals Selects Pharmaceutica... [Published PR Newswire: Health - Oct 16 2014]
EDISON, N.J., Oct. 16, 2014 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has entered into an agreement ...
SELLAS selects PPD as strategic CRO partner to ... [Published PBR - News - Oct 15 2014]
SELLAS Life Sciences Group, a Swiss-based development-stage biopharmaceutical company, has signed a definitive master service agreement with Pharmaceutical Product Development (PPD), a leading global contract research organization (CRO), to advance and ...
SELLAS Life Sciences Group Selects PPD As Its S... [Published PR Newswire: Financial Services - Oct 14 2014]
ZUG, Switzerland and NEW YORK, Oct. 14, 2014 /PRNewswire/ -- SELLAS Life Sciences Group (SELLAS), a Swiss-based development-stage biopharmaceutical company, today announced that it has signed a definitive master service agreement with Pharmaceutical Product ...
Knight Therapeutics Inc. Expands Its Innovative... [Published Marketwire - Breaking News Releases - Oct 02 2014]
MONTREAL, QUEBEC--(Marketwired - Oct. 2, 2014) - Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that it has expanded its innovative pharmaceutical product sourcing strategy for the ...
1 2 3 4 5

Press Releases

sort by: Date | Relevance
National Asset Services Finalizes Lease Agreeme... [Published Financial Services - Jun 12 2014]
Jazz Pharmaceuticals Announces Acquisition From... [Published PR Newswire - Jan 13 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.